Literature DB >> 9672531

Second-degree atrioventricular heart block after doxapram administration.

G S De Villiers1, A Walele, P L Van der Merwe, N N Kalis.   

Abstract

Doxapram, a respiratory stimulant, is used to treat idiopathic apnea of prematurity. The side effects reported are minimal. We present three cases of second-degree atrioventricular block caused by QT interval prolongation associated with doxapram administration. All three infants returned to normal sinus rhythm after doxapram administration was stopped.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9672531     DOI： 10.1016/s0022-3476(98)70197-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  A new look at the respiratory stimulant doxapram.

Authors:  C Spencer Yost
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 2.  Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation.

Authors:  D J Henderson-Smart; P G Davis
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Doxapram Treatment for Apnea of Prematurity: A Systematic Review.

Authors:  Roseanne J S Vliegenthart; Christine H Ten Hove; Wes Onland; Anton H L C van Kaam
Journal:  Neonatology       Date:  2016-10-20       Impact factor: 4.035

Review 4.  Risks and benefits of therapies for apnoea in premature infants.

Authors:  J M Hascoet; I Hamon; M J Boutroy
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

Review 5.  Treatment of apnea of prematurity.

Authors:  Varsha Bhatt-Mehta; Robert E Schumacher
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Precision Dosing of Doxapram in Preterm Infants Using Continuous Pharmacodynamic Data and Model-Based Pharmacokinetics: An Illustrative Case Series.

Authors:  Jarinda A Poppe; Willem van Weteringen; Lotte L G Sebek; Catherijne A J Knibbe; Irwin K M Reiss; Sinno H P Simons; Robert B Flint
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

7.  The bioavailability and maturing clearance of doxapram in preterm infants.

Authors:  Robert B Flint; Sinno H P Simons; Peter Andriessen; Kian D Liem; Pieter L J Degraeuwe; Irwin K M Reiss; Rob Ter Heine; Aline G J Engbers; Birgit C P Koch; Ronald de Groot; David M Burger; Catherijne A J Knibbe; Swantje Völler
Journal:  Pediatr Res       Date:  2020-07-22       Impact factor: 3.756
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.